|
|
| De Souza,C.A.; Santini,G.; Marino,G.; Nati,S.; Congiu,A.M.; Vigorito,A.C.; Damasio,E.. |
| Clinical trials indicate that amifostine may confer protection on various normal tissues without attenuating anti-tumor response. When administered prior to chemotherapy or radiotherapy, it may provide a broad spectrum of cytoprotection including against alkylating drugs. The mechanism of protection resides in the metabolism at normal tissue site by membrane-bound alkaline phosphatase. Toxicity of this drug is moderate with hypotension, nausea and vomiting, and hypocalcemia being observed. We report a phase II study using amifostine as a protective drug against high-dose cyclophosphamide (HDCY) (7 g/m2), used to mobilize peripheral blood progenitor cells (PBPC) and to reduce tumor burden. We enrolled 29 patients, 22 (75.9%) affected by aggressive and 7... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Amifostine; Cytoprotection; Non-Hodgkin's lymphoma; High-dose cyclophosphamide; Peripheral blood progenitor cell mobilization. |
| Ano: 2000 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2000000700009 |
| |
